Skip to content
AnalystLens

Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2025

Filing Date
Filed July 30, 2025
Period End
June 30, 2025
Security
NBIX
One revenue dollarkept$0.16
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported second-quarter 2025 results in this Form 10-Q for the quarter ended June 30, 2025.

Total revenues were $687.5 milliona for the three months ended June 30, 2025, up from $590.2 million a year earlier, driven by net product sales of INGREZZA ($624.4 million) and the newly launched CRENESSITY ($53.2 million). Net income was $107.5 million, or $1.06 per diluted share, compared with $65.0 million, or $0.63 per diluted share, in the prior-year quarter. For the six months ended June 30, 2025, total revenues were $1,260.1 million and net income was $115.4 million, compared with $1,105.5 million and $108.4 million in the first half of 2024.

Research and development expense rose to $244.3 millionb in the quarter from $191.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, and selling, general and administrative expense rose to $286.3 million from $242.0 million. As of June 30, 2025, the company reported total cash, cash equivalents and marketable securities of $1,849.4 million, compared with $1,815.6 million at December 31, 2024. Cash flows from operating activities were $166.8 million for the first six months of 2025, versus $194.9 million a year earlier.

During the first six months, the company repurchased $167.7 millionc of common stock under its 2025 Repurchase Program, leaving $332.3 million available. Management stated that existing capital resources and anticipated product sales are expected to fund operations for at least the next 12 months. The filing also highlights litigation with Zydus over a generic version of INGREZZA SPRINKLE, filed after a Paragraph IV certification in March 2025, and notes that the One Big Beautiful Bill Act, signed July 4, 2025, will be reflected in the third-quarter report as the company continues evaluating its effects.

Key Highlights

  1. Total revenues of $687.5 million in Q2 2025, up from $590.2 million in Q2 2024; INGREZZA net product sales were $624.4 million and CRENESSITY net product sales were $53.2 million.
  2. Net income of $107.5 million in Q2 2025 versus $65.0 million in Q2 2024; diluted EPS of $1.06 versus $0.63.
  3. Research and development expense of $244.3 million in Q2 2025 versus $191.1 million, driven by Phase 3 programs for osavampator (MDD) and NBI-1117568 (schizophrenia).
  4. Selling, general and administrative expense of $286.3 million in Q2 2025 versus $242.0 million, reflecting commercial organization investment and CRENESSITY launch activities.
  5. Total cash, cash equivalents and marketable securities of $1,849.4 million at June 30, 2025, compared with $1,815.6 million at December 31, 2024.
  6. Repurchased $167.7 million of common stock in the first six months of 2025 under the $500.0 million 2025 Repurchase Program; $332.3 million remained available at June 30, 2025.
  7. Phase 3 valbenazine adjunctive treatment study in schizophrenia did not meet its primary endpoint; ongoing Zydus ANDA patent litigation concerns INGREZZA SPRINKLE.

Follow one dollar

Of each $1.00 of revenue in Q2 FY2025, Neurocrine Biosciences kept $0.16.

  1. Revenue$687.5M100.0%
  2. Cost of revenue−$11.3M1.6%
  3. Gross profit$676.2M98.4%
  4. Operating costs−$530.6M77.2%
  5. Operating income$145.6M21.2%
  6. Interest, other & tax−$38.1M5.5%
  7. Net income$107.5M15.6%
Computed from 10-QQ2 FY2025filed July 30, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q2 FY2025 against Q2 FY2024

Line itemQ2 FY2025Q2 FY2024Change
Revenue$687.50M$590.20M+16.5%
Cost of Revenue$11.30M$9.20M+22.8%
Gross Profit$676.20M$581.00M+16.4%
SG&A Expenses$286.30M$242.00M+18.3%
Operating Expenses$541.90M$444.80M+21.8%
Operating Income$145.60M$145.40M+0.1%
Net Income$107.50M$65.00M+65.4%
EPS (Basic)$1.09$0.64+70.3%
EPS (Diluted)$1.06$0.63+68.3%
Shares Outstanding (Basic)99.00M100.80M−1.8%
Shares Outstanding (Diluted)101.00M103.90M−2.8%

Frequently Asked Questions

  1. How did Neurocrine's revenue and profitability change in the second quarter of 2025?

    Total revenues rose to $687.5 million from $590.2 million, led by INGREZZA net product sales of $624.4 million and first-quarter-launched CRENESSITY sales of $53.2 million. Net income increased to $107.5 million, or $1.06 per diluted share, from $65.0 million, or $0.63 per diluted share, in the prior-year quarter. Operating income was $145.6 million, essentially flat compared with $145.4 million a year earlier.

  2. What drove the increase in operating expenses?

    Research and development expense increased to $244.3 million from $191.1 million, primarily reflecting Phase 3 investment in osavampator for major depressive disorder and NBI-1117568 for schizophrenia. Selling, general and administrative expense increased to $286.3 million from $242.0 million, reflecting continued commercial organization investment and CRENESSITY launch activities.

  3. How is the company's liquidity and capital allocation positioned?

    Total cash, cash equivalents and marketable securities were $1,849.4 million at June 30, 2025, and total working capital was $1,202.6 million. Operating cash flow was $166.8 million for the first six months of 2025, and the company used $167.7 million to repurchase common stock. Management believes existing resources will be sufficient to fund operations for at least the next 12 months.

  4. What legal and regulatory matters does the filing disclose?

    Neurocrine disclosed that Zydus filed an ANDA seeking approval of a generic version of INGREZZA SPRINKLE with a Paragraph IV certification, and the company sued Zydus in the District of Delaware and the District of New Jersey in April 2025. The company also disclosed a January 2025 suit against Spruce Biosciences over one of its patents, which the court dismissed without prejudice in June 2025. The company also noted that the One Big Beautiful Bill Act, signed July 4, 2025, will be reflected in its third-quarter 2025 report.